NCT02326051View on ClinicalTrials.gov

Timing of Initiation of LMWH Administration in Pregnant Women With APS

PHASE4CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 31, 2014

Primary Completion Date

February 28, 2017

Study Completion Date

May 31, 2017

Conditions
Recurrent MiscarriageAntiphospholipid Syndrome
Interventions
DRUG

Enoxaparin

Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy

DRUG

Enoxaparin

Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy

Trial Locations (2)

35111

Obstetrics and Gynecology Department in Mansoura University Hospital, Al Mansurah

Unknown

Private practice settings, Al Mansurah

All Listed Sponsors
lead

Mohamed Sayed Abdelhafez

OTHER

NCT02326051 - Timing of Initiation of LMWH Administration in Pregnant Women With APS | Biotech Hunter | Biotech Hunter